FDA expands approval of Modernas RSV vaccine to some adults under age 60
(NEW YORK) -- The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.Previously, the vaccine, known as mRESVIA, had been licensed for... Read More.
